Cargando…
α-Radioimmunotherapy with (213)Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
In spite of development of molecular therapeutics, multiple myeloma (MM) is fatal in most cases. CD38 is a promising target for selective treatment of MM. We tested radioimmunoconjugates consisting of the α-emitter (213)Bi coupled to an anti-CD38 MAb in preclinical treatment of MM. Efficacy of (213)...
Autores principales: | Teiluf, Katharina, Seidl, Christof, Blechert, Birgit, Gaertner, Florian C., Gilbertz, Klaus-Peter, Fernandez, Vanesa, Bassermann, Florian, Endell, Jan, Boxhammer, Rainer, Leclair, Stephane, Vallon, Mario, Aichler, Michaela, Feuchtinger, Annette, Bruchertseifer, Frank, Morgenstern, Alfred, Essler, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467108/ https://www.ncbi.nlm.nih.gov/pubmed/25576914 |
Ejemplares similares
-
Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
por: Wulbrand, Christian, et al.
Publicado: (2013) -
Diverse metabolic response of cancer cells treated with a (213)Bi-anti-EGFR-immunoconjugate
por: Feuerecker, Benedikt, et al.
Publicado: (2021) -
Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide (213)Bi-DTPA-[F3](2) into the Nucleus of Tumor Cells
por: Drecoll, Enken, et al.
Publicado: (2009) -
Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.
por: King, D. J., et al.
Publicado: (1995) -
Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the (213)Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
por: Gustafsson-Lutz, Anna, et al.
Publicado: (2017)